Oxfam is closely watching the outcome of Novartis’ endless and highly
damaging challenge to Section 3(d) of India’s Patent Act. We are profoundly disappointed that Novartis has continued to pursue legal action against the Indian Government. Five years ago, hundreds of thousands of people called upon Novartis to drop its legal challenge against the Indian. Today, over 2 billion people still lack regular access to affordable medicines, and yet Novartis has persisted. Oxfam is seriously concerned that if Novartis succeeds, it will lead to long term and profound changes in India’s patent system that will undermine generic competition and access to affordable,low-cost medicines.
- US continues to keep India on intellectual property priority watch list
- On IP Protection, USTR Finds Fault With China, India … And Switzerland?
- US Special 301 inconsistent with WTO rules, says India
- Member of Parliament concerned on IPR discussions in RCEP can impact access to medicines
- ‘Secretive’ patent talks is worrying generic drug activists